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ABSTRACT 
Olive oil is the primary source of fat in the Mediterranean diet, which is associated 
with a significant improvement in health status, as measured by reduced mortality 
from several chronic diseases. The current pandemic of obesity, metabolic syndrome, 
and type 2 diabetes is intimately associated with an atherogenic dyslipidemic 
phenotype. The core components of the dyslipidemia of the metabolic syndrome, 
which most likely initiate atherosclerosis, are the “lipid triad” of high plasma 
triglycerides, low levels of high-density lipoproteins, and a preponderance of small, 
dense low-density lipoproteins at fasting. However, postprandial (non-fasting) TG 
(postprandial hyperlipidemia) are also recognized as an important component for 
atherosclerosis. Herein, the purpose of this review was to provide an update on effects 
and mechanisms related to the olive oil on postprandial hyperlipidemia and its 
implications for the onset and progression of atherosclerosis and metabolic syndrome. 
 
Keywords: Olive oil, postprandial hyperlipidemia, atherosclerosis, metabolic 
syndrome, lipoproteins, cardiovascular diseases
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OLIVE OIL 
Generalities 
 Virgin olive oil plays a pivotal role as the main source of fat in the 
Mediterranean diet, declared by the UNESCO as an Intangible Cultural Heritage since 
2013. This diet that has traditionally been linked to longevity in Mediterranean 
populations and is associated with a significant improvement in health status, as 
measured by reduced mortality from several chronic diseases.
1 
 According to EC Regulations (EU Regulation 1348/2013; EU 
Regulation 29/2012; EEC Regulation 1513/2001), virgin olive oils are those obtained 
from the mesocarp of the drupe from the fruit of the olive tree (Olea europaea L.), 
obtained exclusively from fresh and healthy olives by physical procedures under low 
thermal conditions (<27°C). Spain is by far the largest producer of virgin olive oil in 
the world, accounting for approximately 50% (≈1,600,000 tons) of total global 
production in 2015.
2
 
 Extra virgin olive oil is a virgin olive oil whose free acidity, expressed 
as oleic acid, is not more than 0.8 gram per 100 grams and organoleptic 
characteristics (flavour and colour) are excellent (for olive oil classification and 
definitions see Ref.
3
). The levels of fatty acids (FAs) in virgin olive oils vary during 
the different maturation stage of the olives, the variety, and the growing conditions. It 
is generally accepted that cooler areas will give oil with higher monounsaturated FAs 
(MUFAs) content than warmer climates.
4 
 The composition of virgin olive oil includes minor compounds 
(unsaponifiable fraction) that could range from one to 3% of the oil.
5
 The constituents 
of minor compounds are present in low concentrations but they are responsible for the 
unique and delicate flavour of virgin olive oil (aldehydes, alcohols, esters, 
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hydrocarbons, ketones, furans, and others). This fraction contains important bioactive 
compounds. 
Brief description of olive oil composition 
 FAs are carboxylic acids and often contain a long, unbranched aliphatic 
chain. FAs are categorized as saturated (SFAs), MUFAs, and polyunsaturated 
(PUFAs) based on their structural and chemical properties. SFAs do not contain any 
double bonds or other functional groups along the chain, which is fully saturated with 
hydrogen atoms. The principal dietary SFAs are palmitic (16:0) and stearic (18:0) 
acids, which are composed of 16 and 18 carbon atoms, respectively. MUFAs contain 
one pair of carbon atoms linked by a cis double bond. Oleic acid (18:1n−9), which 
contains 18 carbon atoms with a double bond at the 9
th
 carbon from the methyl end of 
the FA molecule, is the major dietary MUFA and represents 55 to 83% of the total 
FAs in virgin olive oil (Table 1). Carbon chains containing 2 or more cis double 
bonds, with the first double bond located between either the 3
rd
 and 4
th
 or the 6
th
 and 
7
th
 carbon atoms from the methyl end of the FA molecule, belong to the n−3 or n−6, 
respectively, PUFA families. These families cannot be synthesized by the human 
body (double bonds can be introduced into all positions of the FA chain with the 
exception of the n−3 and n−6 positions) and therefore must be obtained from the diet 
as -linolenic acid (18:3n−3) and linoleic acid (18:2n−6) or their long-chain PUFA 
derivatives. Of these FAs, eicosapentaenoic acid (EPA, 20:5n−3), docosahexaenoic 
acid (DHA, 22:6n−3), dihomo-γ-linolenic acid (20:3n−6), and arachidonic acid (AA, 
20:4n−6) are the most metabolically significant.
6
 The concentrations of SFAs 
(palmitic + stearic acids) and PUFAs (α-linolenic + linoleic acids) in virgin olive oil 
range from 8 to 26% and from 3 to 22% of the total FAs, respectively. 
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 Oleic acid is the primary component of virgin olive oil (≈83% oleic acid 
in position sn−2 of the triglycerides, TGs) and is also found in peanut oil (≈59% oleic 
acid) and canola oil (≈37% oleic acid). Oleic acid is a key component of TGs and 
membrane lipids.
7
 Importantly, oleic acid is the most common FA in nature, as well 
as in our diet (generally, oleic acid supplies an amount of calories equivalent or 
greater than the amount provided by SFAs and PUFAs combined). Tight restrictions 
on SFA consumption (<10% of total daily calories; less than 7% for high-risk 
individuals) and PUFA consumption (<5%) have been recommended. By contrast, 
oleic acid may provide up to 20–25% of total daily calories. 
 The unsaponifiable fraction of virgin olive oil contains highly bioactive 
compounds (>200 constituents) (Table 2). Despite their wide variety and nutritional 
significance, they commonly account up to 3% of the total oil composition (reaching 
individual concentrations as smaller as ppm).
8
 This fraction is fundamental in 
contributing to specific characteristics of virgin olive oil, such as its oxidative stability 
and its special flavour (aroma and taste) as well as its colour.
9 
 Among the several minor compounds of virgin olive oil (Figures 1–3), 
the most abundant fraction is hydrocarbons (squalene and, in smaller amounts, the 
carotenoids β-carotene and lutein). Other minor compounds of virgin olive oil include 
phytosterols, such as β-sitosterol, ∆5-avenasterol, and campesterol; triterpenic 
compounds in the form of dialcohols (erythrodiol and uvaol) or acids (oleanolic and 
maslinic acids); and phenolic compounds, representing the polar fraction. The main 
classes of phenolic compounds in virgin olive oil are secoiridoids, as ester derivatives 
of elenolic acid in either its aglyconic form or glycosylated with hydroxytyrosol 
(oleuropein) or tyrosol (ligustroside); simple phenols, in the form of alcohols (tyrosol 
and hydroxytyrosol) or acids (p-coumaric, o-coumaric, caffeic, ferulic, sinapic, gallic, 
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gentisic, syringic, vanillic, protocathechuic, and p-hydroxybenzoic acids); 
hydroxyisochromans formed by the reaction between hydroxytyrosol and 
benzaldehyde or vanillin; flavonoids (luteolin, apigenin, and quercetin); and the 
lignans (+)-pinoresinol, 1-(+)-acetoxypinoresinol, and 1-(+)-hydroxypinoresinol. The 
lipophilic phenols include tocopherols α- β-, γ-, and δ-tocopherols) and 
tocotrienols α- β-, γ-, and δ-tocotrienols), with α-tocopherol as the predominant 
constituent in virgin olive oil. It is important to note that only virgin olive oil contains 
minor compounds, since mostly of them disappear during refining processes.
6,9 
Digestion of triglycerides of olive oil and absorption of oleic acid and other fatty 
acids 
 In general, the first event in the transformation of insoluble oil into 
soluble and absorbable lipids is the formation of an initial emulsion (chyme) by 
mastication in the mouth where the dispersion of TGs happens. The surface area of 
TGs is then increased, which benefits their emulsion (formation of lipid droplets) in 
the stomach. During the initial gastric process, partially emulsified TGs are attached 
by lingual and gastric lipases.
10 
 Gastric lipase activity does not contribute to the hydrolysis of 
phospholipids (PLs) and cholesteryl esters (CEs), and is functional in the pH range of 
3 to 6. In the stomach, this enzyme hydrolyses only 10 to 30% of ingested TGs 
because of an inhibition process induced by the long-chain free FAs (FFAs) 
generated, which are mostly protonated at gastric pH. It explains the limited lipolysis 
of TGs under gastric conditions regarding the complete TGs hydrolysis by pancreatic 
lipase in the duodenum.
11,12 
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 During gastric lipolysis, FFAs have higher affinity for the surface than 
the core of the lipid droplets.
13
 There is a considerable fusion between lipid droplets, 
probably due to the presence of FFAs, monoglycerides (MGs), and diglycerides 
(DGs) that are known to be fusogenic. This change in the lipid composition of the 
droplet surface during lipolysis could modify the interfacial tension or the surface 
pressure and could then interfere with gastric lipase binding and activity.
14
 The 
accumulation of FFAs at the droplet surface leads to an inhibition of lipolysis by 
gastric lipase. The mechanism by which this happens is attributed to the formation of 
clusters at the surface of the lipid droplets. In the intestine, the smaller size of lipid 
droplets increases proportionally the lipid surface exposed to the pancreatic lipase.
15
 
The FAs released from the initial gastric lipolysis and the amino acids and peptides 
formed by gastric proteolytic activity stimulate specific receptors in intestinal 
epithelial cells to secrete cholecystokinin. It stimulates gallbladder contraction 
delivering bile salts to the duodenum. The fat droplets covered with bile salts are not 
accessible to pancreatic lipase, but the co-lipase enzyme allows the pancreatic lipase 
molecule to bind to the lipid aqueous interface and facilitates the stabilization of 
emulsified TGs. Pancreatic lipase cleaves the sn-1 and sn-3 positions of TGs 
obtaining sn-2 MGs and FFAs.
16
 In olive oil, up to 83% of total sn-2 positions in TGs 
are occupied by oleic acid, which means that olive oil acts as a supplier of oleic acid-
rich hydrocarbon skeletons and free oleic acid for energy or for cellular synthesis of 
TGs and PLs.
17 
 Absorption of lipid molecules, such as sn-2 MGs and oleic acid, takes 
place along the epithelial cells of the small intestine, mainly in the proximal jejunum 
but also in parts that are more distal. The epithelial cells of the small intestine show an 
apical membrane with a brush border made up of many microvilli, which have a 
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width of about 100 nm and being much smaller (5-20 nm) the spaces between them. 
Lipid metabolites generated throughout the digestion of olive oil are more polar than 
the parent TGs, but they still have a limited solubility in the aqueous environment of 
the intestinal lumen. Micelles and sub-micelles are the main vehicles for 
approximating sn-2 MGs and FFAs successfully to the membrane of the microvilli. 
There, the acidic microclimate (pH 5.3-6) promotes both micellar dissociation and FA 
protonation, facilitating the passive diffusion of FFAs across the cellular membrane.
18
 
Enterocytes may also take up FFAs via energy dependent and carrier-mediated 
processes. It is known the existence of two isotypes (I and L) of FA binding proteins 
(FABPs), which differ in their binding specificity. I-FABP binds strongly to FFAs, 
whereas L-FABP preferentially binds to sn-2 MGs.
19
 These carriers play an important 
role at low FFA concentrations (probably to ensure sufficient uptake of lipid 
nutrients), whereas passive diffusion predominates at high FFA concentrations. Other 
proteins, including GP330 (megalin), CD36, SR-BI, and caveolin can bind lipids and 
related metabolites.
20
 Differences in the rate of absorption of FFAs have been 
described as a function of chain length and of number and place of double bonds.
21
 
Short-chain (2-4 carbon atoms) and medium-chain (6-12 carbon atoms) FAs are more 
rapidly absorbed than FAs of more than 14 carbon atoms, because they do not need 
micellar solubilisation, just bound to albumin and are transported directly to the liver 
by the portal vein.
22 
Assembly of intestinal lipoproteins containing triglycerides from olive oil ingestion 
 In the enterocyte, FFAs (mainly oleic acid) from absorption and the pool 
of endogenous metabolism, together with sn-2 MGs, are used for re-synthesis of TGs. 
This process is initiated with the activation of FFAs to the corresponding acyl-CoA. 
In this form, FFAs are sequentially transferred to sn-2 MGs by MG and DG 
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acyltransferases. These enzymes form a complex called ‘‘triglyceride synthetase’’,
23
 
and the pathway favours the stereospecific reacylation at the sn-1 position. It 
contributes to 80% of the intestinal TG re-synthesis in the fed state. Acyl-CoA can 
also be transferred to α-glycerophosphate (derived from glucose metabolism) by the 
phosphatidic acid pathway, which accounts for the remaining 20%.
21
 The composition 
of these novel TGs closely resembles the composition of TGs from olive oil.
24
 These 
TGs are coated with cholesterol, PLs, and one molecule of apolipoprotein (apo) B48 
at the rough and smooth endoplasmic reticulum in a microsomal TG transfer protein 
(MTP)-dependent step,
25
 and further processed in the Golgi apparatus before being 
released as chylomicrons (CMs) by the enterocyte through exocytosis. It occurs 
through the basolateral membrane of enterocytes and CMs enter the lymphatic 
capillaries of intestinal microvilli that drain into lymphatic channels, reaching the 
systemic circulation through the thoracic duct.
26
 The body can also secrete very low-
density lipoproteins (VLDLs). While CMs are of intestinal origin and formed after the 
ingestion of fatty meals, VLDLs are the major lipoproteins secreted by the liver 
during fasting.
21
 Both CMs and VLDLs are considered TG-rich lipoproteins (TRLs). 
POSTPRANDIAL HYPERLIPIDEMIA 
Generalities 
 Postprandial hyperlipemia is a normal and transient physiological 
phenomenon that occurs in response to the ingestion of a fatty meal. Dietary lipids are 
absorbed as described above and intestinally secreted TRLs have the function to 
stabilize the absorbed dietary lipids for transport in the aqueous plasma environment 
and to provide cells with exogenous FAs by receptor (e.g., apoB48 receptor, LDL 
receptor, and LDL receptor-related protein) or non-receptor-dependent mechanisms 
for energy and numerous metabolic pathways.
27
 In healthy people, the levels of 
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plasma TGs usually peak 3-4 h after a fat meal and tend to return to baseline within 6-
8 h (Figure 4). However, postprandial hyperlipemia can become pathological when 
magnitude and duration of TRL response is exacerbated, resulting in the accumulation 
of postprandial TRLs and their remnants in the circulation.
28
 In that cases, the 
postprandial hyperlipemic peak may be two to three fold higher than normal and 
prolonged, even up to 10-12 h after the dietary fat ingestion.
29 
Postprandial hyperlipemia and atherosclerosis 
 Zilversmit first described postprandial hyperlipemia as an atherogenic 
phenomenon in 1979.
30
 Later, it received more attention after the discovery of 
postprandial TRLs as cholesterol-independent atherogenic particles
31
 and postprandial 
abnormalities in the TG metabolism as a hallmark of patients with established 
coronary heart disease (CHD).
32
 The identification of postprandial TRLs (by means of 
apoB48) in human atheroma has provided further evidence for their direct role in 
atherogenesis.
33
 The greater the magnitude and duration of the postprandial TRL 
response, the greater the exposure of the arterial wall to postprandial TRLs (and their 
remnants) and the greater the likelihood that TGs will replace CEs in LDL-C and 
HDL-C particles. Postprandial TRLs can penetrate the arterial wall and can reach the 
subendothelial space (Figure 5), causing endothelial lipid (notably TG) deposits, 
attraction of monocytes, production of inflammatory markers, and oxidative stress.
34-
36
 The role of TGs in atherosclerosis-mediated inflammation not only depends on 
their direct vascular effects, but it is also related to profound changes in the 
functionality of HDL-C that include protection against vessel inflammation or 
disorders of immune response.
37 
 Prospective epidemiology on non-fasting levels of plasma TGs in 
response to normal food intake include three large-scale studies: the Copenhagen City 
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Heart Study,
38
 Women’s Health Study,
39
 and the Norwegian Counties Study;
40
 all of 
which have demonstrated that: (i) non-fasting levels of plasma TGs are increased 
among populations with established cardiovascular disease (CVD) or with multiple 
risk factors predisposing to CVD; and (ii) long-term follow-up of subjects in 
prospective, population-based studies links non-fasting (and, less robustly, fasting) 
TGs to the incidence of CVD events or deaths.
41
 Many patients with CVD remain at 
high risk for CVD events even when the LDL-C goal has been achieved with lipid-
lowering therapy.
42
 These lines of evidence indicate that non-fasting levels of plasma 
TGs may be predictive and independent of traditional LDL-C-related risk of CVD.  
Postprandial hyperlipemia and metabolic syndrome 
 Metabolic syndrome (MetS) is a major and escalating public health and 
clinical challenge worldwide in the wake of urbanization, surplus energy intake, 
increasing obesity, and sedentary life habits. It is estimated that around 20-25% of the 
world’s adult population has MetS. In Spain, a national survey reported that the 
prevalence of MetS reached up to 30% in 2010 (Figure 6).
43
 MetS confers a 5-fold 
increase in the risk of type-2 diabetes (T2D) and 2-fold the risk of CVD over the next 
5 to 10 years.
44
 Further, patients with MetS are at 2- to 4-fold increased risk of stroke, 
a 3- to 4-fold increased risk of myocardial infarction (MI), and 2-fold the risk of 
dying from such events compared with those without MetS
45
 regardless of a previous 
history of cardiovascular problems.
46
 MetS is considered as a first order risk factor for 
atherothrombotic complications and its presence or absence should therefore be 
considered an indicator of long-term risk. 
 MetS is defined by a constellation of an interconnected physiological, 
biochemical, clinical, and metabolic factors that directly increase the risk of 
atherosclerotic CVD, T2D, and all causes of mortality.
47,48
 This collection of 
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unhealthy body measurements and abnormal laboratory test outcomes includes 
atherogenic dyslipidemia, hypertension, glucose intolerance, and pro-inflammatory 
and pro-thrombotic states.
49,50
 There have been several definitions of MetS, but the 
most commonly used criteria for definition at present are from the World Health 
Organization (WHO),
51
 the European Group for the study of Insulin Resistance 
(EGIR),
52
 the National Cholesterol Education Programme Adult Treatment Panel III 
(NCEP ATP III),
53
 the American Association of Clinical Endocrinologists (AACE),
54
 
and the International Diabetes Federation (IDF) (Tables 3 and 4). 
 The core components of the atherogenic dyslipidemia in MetS are the 
“lipid triad” of high plasma TGs, low levels of HDL-C, and a preponderance of small, 
dense LDL-C at fasting.
56,57
 Several studies have described abnormalities during the 
postprandial state in patients with CHD,
58
 showing that non-fasting TGs is an 
independent predictor of CHD in multivariate analysis,
59
 even after adjustment for 
fasting TGs or HDL-C in normolipidemic men. Elevated non-fasting TGs are often 
found in insulin-resistant subjects. Some reports have indicated that postprandial 
hyperinsulinemia and/or decreased insulin sensitivity are also involved in altered 
acute metabolism of dietary fats.
60
 The decreased insulin sensitivity commonly 
associated with obesity
61
 and the fat abdominal accumulation
62
 may well play an 
important part in the development of MetS. 
 One challenge aspect of MetS is to understand the cellular mechanisms 
that link the metabolic abnormalities with the pathophysiological effects that generate 
this disease. One important link has been derived from the finding that pro-
inflammatory cytokines are overexpressed during fat abdominal accumulation, which 
later will lead to several obesity-related disorders.
63
 Adipose tissue is a heterogeneous 
mix of adipocytes, stromal pre-adipocytes, immune cells, and endothelium, which can 
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respond rapidly and dynamically to alterations under nutrient excess through 
adipocyte hypertrophy and hyperplasia.
64
 With obesity and progressive adipocyte 
enlargement, the blood supplied to adipocytes may be reduced with consequent 
hypoxia.
65
 This condition of inadequate oxygen supply has been proposed to be an 
inciting aetiology of adipocyte necrosis and macrophage infiltration into adipose 
tissue, leading to an overproduction of pro-inflammatory factors (e.g., adipokines) 
and to a local inflammation that propagate an overall systemic inflammation 
associated with the development of obesity-related comorbidities.
66
 Tumour necrosis 
factor-alpha (TNF-α), adiponectin, visfatin/NAMPT (nicotinamide 
phosphoribosyltransferase), and interleukin-6 (IL-6) are among the most important 
adipokines involved in the pathogenesis of MetS and produced by adipocytes and by 
infiltrated macrophages into adipose tissue.
67 
 TNF-α is a pro-inflammatory cytokine that exerts numerous effects in 
adipose tissue including on lipid metabolism and insulin signalling. An increase in 
TNF-α promotes the secretion of other pro-inflammatory cytokines, such as IL-6, and 
reduces the production of anti-inflammatory cytokines, such as adiponectin.
68
 There is 
evidence suggesting that TNF-α may induce apoptosis in adipocytes
69
 and may 
promote peripheral insulin resistance by the inhibition of the insulin receptor substrate 
1 signalling pathway.
70
 Adiponectin exerts an anti-inflammatory activity and 
modulates insulin sensitivity by stimulating glucose utilization and FA oxidation.
71
 
Adiponectin is almost exclusively secreted by adipose tissue. Its levels decrease in 
obesity and are inversely correlated with visceral adipose tissue accumulation.
72 
 Visfatin/NAMPT is a protein with several functions. Although the first 
discovery of this molecule as a pre-B-cell colony-enhancing factor suggested 
primarily a cytokine function, its rediscovery as the key enzyme in nicotinamide 
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(NAM) adenine dinucleotide (NAD
+
) generation has considerably widened its 
potential biological activities.
73
 Although originally produced in adipose tissue by 
adipocytes and infiltrating macrophages, it seems to be secreted by other cells and 
tissues such as skeletal muscle, liver, immune cells, cardiomyocytes, and brain.
74
 
Visfatin/NAMPT has a broad spectrum of effects and is mirrored by its potential 
involvement in a wide range of disorders, including MetS, myocardial failure, 
atherosclerosis, inflammatory diseases, malignancies, neurodegenerative disorders, 
and aging.
75 
 IL-6 is a multifaceted, pleiotropic cytokine that is a central player in the 
regulation of inflammation, haematopoiesis, immune responses, and host defence 
mechanisms.
76
 Because one-third of circulating IL-6 in healthy individuals is 
estimated to originate from adipose tissue, IL-6 is considered an adipokine. Moreover, 
IL-6 has been found to be crucial in immunoregulation. It can itself enhance 
leukocyte differentiation and proliferation, immunoglobulin secretion, acute phase 
protein production, and macrophage/monocyte activation. IL-6 is considered as an 
early key factor that triggers acute phase reactants and metabolic abnormalities tightly 
associated to inflammatory responses.
77 
Pharmacological approaches affecting postprandial hyperlipemia  
 The large majority of drugs affecting lipid metabolism also affects 
postprandial hyperlipemia; however, well-designed and robust clinical studies in this 
specific field are limited due the difficulties of setting up a postprandial study in a 
large cohort of patients. 
 Improved understanding of the physiology and genetic regulation of 
postprandial TG metabolism could lead to the identification of new targets for 
therapy.
78
 However, data from randomized clinical trials on the benefits of lowering 
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TGs are much less robust than for the benefits of lowering LDL-C with statins as 
inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase.
79,80
 This could be 
due to the lack of high-grade evidence for benefits of TG-lowering drugs, which is 
reflected by the lack of specific target goals for both fasting and non-fasting levels of 
plasma TGs. Appropriate dietary changes limiting fat content, caloric restriction 
resulting in weight loss, restriction of alcohol intake, and increased exercise may be 
fundamental for management of high fasting
28,81,82
 and non-fasting
83-85
 levels of 
plasma TGs. Current guidelines do not stipulate the atherogenic lipid profile in the 
postprandial state as a target for therapy nor do they give any target values for the 
parameters of postprandial hyperlipemia. Statin therapy is recommended as the first 
pharmacological step to reduce elevated levels of plasma TGs in individuals with high 
or very high CVD risk based on global risk assessment, particularly in subjects with 
MetS and T2D.
86
 Available data have pointed that statins also reduce non-fasting 
levels of plasma TGs.
87
 Interestingly, ezetimibe has been reported to reduce apoB48 
secretion in human intestine, suggesting a direct effect of this drug on assembly of 
postprandial TRLs in enterocytes.
88
 Studies on fibrates have given consistent results 
reporting significant lowering of non-fasting levels of plasma TGs in response to a 
standardized fat challenge.
28,88
 Furthermore, fenofibrate also reduced levels of plasma 
apoB48 and biomarkers for postprandial TRL remnants.
89 
 New pharmacological and non-pharmacological approaches, such as 
dual peroxisome proliferator-activated receptor (PPAR)α/PPARδ agonists, dietary 
oils rich in DGs, inhibitors of DG-O-acyltransferase-1, and microsomal TG transfer 
protein, antisense oligonucleotides for apoB100, apoB48, and apoCIII, and incretin-
based treatments could be employed alone or in combination with conventional 
therapies to optimize treatment for management of dyslipidemia due to high fasting 
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and non-fasting levels of plasma TGs.
28
 However, the clinical efficacy, mechanisms 
of action, safety, and tolerability of these newer agents requires further testing in 
clinical trials. 
Conclusions 
 MetS is a major and escalating public health and clinical challenge 
worldwide in the wake of urbanization. The complexity of the molecular 
pathophysiology of MetS requires rational therapeutic and dietary strategies. Olive oil 
is a natural fruit product that contains a unique composition of oleic acid and minor 
constituents. Within this context, the consumption of olive oil has shown a broad 
range of promising activities in the postprandial disturbances. Nonetheless, further 
efforts are needed to mechanistically define the biochemical and biological 
postprandial activities of olive oil on atherosclerosis and MetS. 
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ABBREVIATIONS 
AA: arachidonic acid 
Apo: apolipoprotein 
CE: cholesteryl ester 
CHD: coronary heart disease 
CM: chylomicron 
CVD: cardiovascular disease 
DG: diacylglycerol 
DHA, docosahexaenoic acid 
EPA: eicosapentaenoic acid 
FA: fatty acid 
FABP: fatty acid binding protein 
FFA: free fatty acid 
HDL: high-density lipoprotein 
IL: interleukin 
LDL: low-density lipoprotein 
MCP: monocyte chemotactic protein 
MetS: metabolic syndrome 
MG: monoacylglycerol 
MI: myocardial infarction 
MTP: microsomal triglyceride transfer protein 
MUFA: monounsaturated fatty acid 
NAD: nicotinamide adenine dinucleotide 
NAM: nicotinamide 
NAMPT: nicotinamide phosphoribosyltransferase 
PL: phospholipid 
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PPAR: peroxisome proliferator-activated receptor 
PUFA: polyunsaturated fatty acid 
SFA: saturated fatty acid 
T2D: type-2 diabetes 
TG: triglyceride 
TNF: tumour necrosis factor 
TRL: triglyceride-rich lipoprotein 
VLDL: very low-density lipoprotein 
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Figure Legends 
Figure 1. Chemical structures of squalene, carotenoids, sterols, triterpenic dialcohols, 
and triterpenic acids in virgin olive oil.
6 
Figure 2. Chemical structures of secoiridoids, phenyl-alcohols, and phenyl-acids in 
virgin olive oil.
6 
Figure 3. Chemical structures of hydroxyisochromans, flavonoids, lignans, 
tocopherols, and tocotrienols in virgin olive oil.
6 
Figure 4. Serum TG levels after the ingestion of fatty meals. (A) Serum TG levels 
reach a peak at 3-4 h and slowly return to initial levels at 6-8 h after a fatty meal. (B) 
Most of the day is a non-fasting state (in other words a postprandial state) in people 
who eat at least three fatty meals a day.
58 
Figure 5. Concept of the initiation of atherosclerosis by TRLs: lipoproteins enter the 
subendothelial space via nonspecific transcytotic processes. This is often a non-
pathologic process, because the lipoproteins leave (TRLs with greater difficulty than 
LDL-C) the subendothelial space again via the vasa vasorum. Lipoproteins can be 
easily taken up by macrophages. Circulating TRLs themselves also contribute to the 
presence of subendothelial macrophages. Monocytes can bin and take up TRLs, 
which stimulates monocytes to become activated. Subsequently, activated monocytes 
express adhesion molecules on the outer membrane and stimulate the expression of 
endothelial cellular adhesion molecules (CAMs), which allows monocytes to home 
the endothelium and migrate into the subendothelial space. Finally, the macrophages 
change into highly atherogenic foam cells when lipid uptake exceeds lipid efflux. 
Figure 6. Prevalence of MetS in the Spanish population aged 18 years or older from 
2008 to 2010.
43 
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Table 1. Chemical structure and range of major fatty acids in virgin olive oil. 
Fatty acid Regulations
a 
(%) 
16:0, palmitic acid 
7.5-20.0 
  
16:1n-7, palmitoleic acid 
0.3-3.5 
  
18:0, stearic acid 
0.5-5.0 
  
18:1n-9, oleic acid 
55.0-83.0 
  
18:2n-6, linoleic acid 
3.5-21.0 
 
 
18:3n-3, α-linolenic acid ≤ 1.0 
  
MUFA, monounsaturated fatty acids 55-87 
SFA, saturated fatty acids 8-26 
PUFA, polyunsaturated fatty acids 3-22 
a 
International Olive oil council
6 
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Table 2. Minor compounds in virgin olive oil.
6 
Minor compounds Concentration (mg/kg oil) 
Squalene 
β-carotene and lutein 
Sterols 
Triterpenic compounds 
Phenols 
Tocopherols and tocotrienols 
800-8000 
4-10 
1000-3000 
200-300 
200-1500 
250-350 
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Table 3. Criteria proposed for the clinical diagnosis of MetS.
55 
Clinical 
measures 
WHO (1998) EGIR (1999) 
ATP III 
(2001) 
Insulin 
resistance 
IGT, IFG, 
T2D, or 
lowered insulin 
sensitivity plus 
any 2 of below 
clinical 
measures 
Plasma 
insulin >75
th
 
percentile 
None, but 
any 3 of 
below 
clinical 
measures 
Body weight 
Men: waist-to-
hip ratio >0.90; 
women: waist-
to-hip ratio 
>0.85 and/or 
BMI >30 
kg/m
2
 
WC ≥94 cm 
in men or ≥80 
cm in women 
WC ≥102 
cm in men 
or ≥88 cm in 
women 
Lipids 
(at fasting) 
TGs ≥150 
mg/dL and/or 
HDL-C <35 
mg/dL in men 
or <39 mg/dL 
in women 
TGs ≥150 
mg/dL and/or 
HDL-C <39 
mg/dL in men 
or women 
TGs ≥150 
mg/dL 
HDL-C <40 
mg/dL in 
men or <50 
mg/dL in 
women 
Blood 
pressure 
≥140/90 mm 
Hg 
≥140/90 mm 
Hg or on Rx 
against 
hypertension 
>130/85 mm 
Hg 
Glucose 
(at fasting) 
IGT, IFG or 
T2D 
IGT or IFG 
(but not 
diabetes) 
>110 mg/dL 
(includes 
diabetes) 
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Table 4. Criteria proposed for the clinical diagnosis of MetS.
55 
Clinical 
measures 
AACE (2003) IDF (2005) 
Insulin 
resistance 
IGT or IFG plus any of 
below clinical measures 
None 
Body 
weight 
BMI ≥25 kg/m
2
 
Increased WC (population specific) plus 
any 2 of below clinical measures 
Lipids 
(at fasting) 
TGs ≥150 mg/dL and 
HDL-C <40 mg/dL in 
men or <50 mg/dL in 
women 
TGs ≥150 mg/dL or on Rx against TGs. 
HDL-C <40 mg/dL in men or  <50 
mg/dL in women or on Rx to increase 
HDL-C 
Blood 
pressure 
>130/85 mm Hg 
≥130 mm Hg systolic or ≥85 mm Hg 
diastolic or on RX against hypertension 
Glucose 
(at fasting) 
IGT or IFG (but not 
diabetes) 
≥100 mg/dL (includes diabetes) 
IFG: impaired fasting glucose; IGT: impaired glucose tolerance; Rx: receiving 
treatment; WC: waist circumference. 
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